VEGF 164 組換え体(リコンビナント)タンパク質 | Recombinant Rat VEGF 164
掲載日情報:2015/01/26 現在Webページ番号:113015
R&D Systems社製の高品質なVEGF 164の組換え体タンパク質(Recombinant Rat VEGF 164)です。
※本製品は研究用です。研究用以外には使用できません。
[在庫・価格 :2024年05月18日 10時35分現在]
詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VEGF164, Rat, Recombinant |
|
22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
VEGF164, Rat, Recombinant, Carrier-free |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
[在庫・価格 :2024年05月18日 10時35分現在]
VEGF164, Rat, Recombinant
文献数: 22
- 商品コード:564-RV-050
- メーカー:RSD
- 包装:50μg
- 価格:¥235,000
- 在庫:無(未発注)
- 納期:10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 |
産生:NS0,純度:>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Rat,M.W.:19.2 kDa (monomer),Genbank:7422,エンドトキシンレベル:<0.10 EU per 1 µg of the protein by the LAL method. 別名:MVCD1 Genbank No: 7422 Protein Accession No: AAL07526.1 |
||||||
---|---|---|---|---|---|---|---|
別包装品 | 別包装品あり | ||||||
法規制等 | |||||||
保存条件 | -20℃ | 法規備考 | |||||
掲載カタログ |
|
||||||
製品記事 | |||||||
関連記事 |
VEGF164, Rat, Recombinant, Carrier-free
文献数: 0
- 商品コード:564-RV-050/CF
- メーカー:RSD
- 包装:50μg
- 価格:¥235,000
- 在庫:無(未発注)
- 納期:10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 |
産生:NS0,純度:>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Rat,M.W.:19.2 kDa (monomer),Genbank:7422,エンドトキシンレベル:<0.10 EU per 1 µg of the protein by the LAL method. 別名:MVCD1 Genbank No: 7422 Protein Accession No: AAL07526.1 |
||||||
---|---|---|---|---|---|---|---|
別包装品 | 別包装品あり | ||||||
法規制等 | |||||||
保存条件 | -20℃ | 法規備考 | |||||
掲載カタログ |
|
||||||
製品記事 | |||||||
関連記事 |
追加しました。
バルク注文に関して
※バルク包装品も承ります。お気軽にお問合せ下さい。
追加しました。
CF(Carrier-Free)とは?
R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。
追加しました。
Product Details
- Source
- Mouse myeloma cell line, NS0-derived, Ala27-Arg190
- Accession
- AAL07526.1
- Structure
- Disulfide-linked homodimer
- Purity
- >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
- Predicted Molecular Mass
- 19.2 kDa (monomer)
- SDS-PAGE
- 25 kDa, reducing conditions
- Activity
- Measured in a cell proliferation assay using HUVEC human umbilical vein endothelial cells.Conn, G. et al. (1990) Proc. Natl. Acad. Sci. USA 87
追加しました。
Additional Information
- Molecule Information
- VEGF
- Aliases
- VAS; Vasculotropin; VEGFA; VPF
- Entrez Gene IDs
- 7422 (Human); 22339 (Mouse); 83785 (Rat); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
- Background
- VEGF
- Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. The amino acid sequence of VEGF exhibits primary structural, as well as limited amino acid sequence, homology with that of the A and B chains of PDGF. All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Based on its homology with VEGF, PlGF was also proposed to be an angiogenic factor. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF with high affinity.In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has been shown to stimulate von Willebrand factor release from endothelial cells and induce expression of tissue factor activity in endothelial cells as well as in monocytes. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. It promotes extravasation of plasma fibrinogen, leading to fibrin deposition which alters the tumor extracellular matrix. The modified extracellular matrix subsequently promotes the migration of macrophages, fibroblasts and endothelial cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. Elevated levels of VEGF have been reported in synovial fluids of rheumatoid arthritis patients and in sera from cancer patients.
追加しました。
Citations
Citations of cell biology reagents in peer reviewed literature can be used as a direct measure of product quality. They can also provide crucial insightinto their use under specialized or unique experimental conditions. Because of the importance published citations have to researchers, R&D Systems personnelmanually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but alsoprovides information about sample types, species, and experimental conditions.
A novel nonradioactive method to evaluate vascular barrier breakdown and leakage.
Gragoudas E, Koufomichali X, Manola A, Miller JW, Montezuma S, Morizane Y, Papakostas TD, Thanos A, Trichonas G, Vavvas D, Young L
Invest. Ophthalmol. Vis. Sci. 2010 51:1677-82
Species: Rat
Protein Application: In Vivo
Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration.
Creemers LB, Dhert WJ, Hefferan TE, Heijink A, Kempen DH, Lu L, Maran A, Yaszemski MJ
Biomaterials 2009 30:2816-25
Species: Rat
Protein Application: In Vivo
Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma.
Dong A, Fernandez-Ruiz V, Hu J, Kawa M, Martinez-Anso E, Prieto J, Qian C, Shan J
Cancer Res. 2009 69:6951-9
Species: Mouse
Protein Application: Bioassay
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor.
Brereton HM, Irani Y, Tilton RG
Hybridoma (Larchmt) 2009 28:205-9
Species: Human
Protein Application: Binding Assay
Characterization of azurocidin as a permeability factor in the retina: involvement in VEGF-induced and early diabetic blood-retinal barrier breakdown.
Almulki L, Frimmel S, Gragoudas ES, Hafezi-Moghadam A, Kim IK, Miller JW, Nakazawa T, Noda K, Skondra D, Tayyari F, Thomas KL, Zandi S
Invest. Ophthalmol. Vis. Sci. 2008 49:726-31
Species: Rat
Protein Application: In Vivo
VEGF promotes vascular sympathetic innervation.
Damon DH, Marko SB
Am. J. Physiol. Heart Circ. Physiol. 2008 294:H2646-52
Species: Rat
Protein Application: Bioassay
The effect of sustained delivery of vascular endothelial growth factor on angiogenesis in tissue-engineered intestine.
Ashley SW, Krebs NJ, Leach JK, Mooney DJ, Rocha FG, Sundback CA, Vacanti JP, Whang EE
Biomaterials 2008 29:2884-90
Species: Rat
Protein Application: In Vivo
Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina.
Goldschmeding R, Hughes JM, Klaassen I, Kuiper EJ, Schlingemann RO, Van Geest RJ, Van Noorden CJ, Vogels IM
Invest. Ophthalmol. Vis. Sci. 2007 48:4267-76
Species: Rat
Protein Application: In Vivo
Homogeneous differentiation of hepatocyte-like cells from embryonic stem cells: applications for the treatment of liver failure.
Berthiaume F, Cho CH, Nahmias Y, Parashurama N, Park EY, Park J, Suganuma K, Tilles AW, Yarmush ML
FASEB J. 2007 22:898-909
Species: Rat
Protein Application: Bioassay
Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats.
Asada K, Fukui H, Ikenaka Y, Kitade M, Kojima H, Nakamura M, Namisaki T, Noguchi R, Sakurai S, Uemura M, Yamazaki M, Yanase K, Yoshii J, Yoshiji H
J. Hepatol. 2006 44:568-75
Species: Rat
Protein Application: In Vivo
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。